Company / Capital Expenditures
Amphstar Pharmaceuticals, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$34.9M
FY2025
5-year range
$24.0M / $41.0M
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#31 of 194
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s capital expenditures of $35M is higher than 84% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $21M in FY2016 to $47M in FY2018.
Based on SEC 10-K filings.
$35M in FY2025 with a 5-year CAGR of +0.6%. Top quartile in the Health Care sector.
Declined from $38M to $35M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +13.2%
- 5-Year CAGR
- +0.6%
- 10-Year CAGR
- -
Sector benchmark
-70.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.6%, indicating consistent growth.
- In FY2025, capital expenditures decreased 15.0% year-over-year.
- Ranks #31 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.9M | -15.0% |
| FY2024 | $41.0M | +7.5% |
| FY2023 | $38.2M | +58.8% |
| FY2022 | $24.0M | -12.5% |
| FY2021 | $27.5M | -18.9% |
| FY2020 | $33.9M | -18.5% |
| FY2019 | $41.6M | -11.2% |
| FY2018 | $46.8M | +33.4% |
| FY2017 | $35.1M | +64.2% |
| FY2016 | $21.4M | +33.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026